Autonomix Medical CEO Brad Hauser joined Steve Darling from Proactive to announce a significant milestone in the company’s development of breakthrough neuro-modulation technology. The company has released a compelling new video testimonial from a patient who participated in the initial phase of its first-in-human proof-of-concept trial, which is evaluating a novel method of delivering transvascular energy to ablate nerves and alleviate severe pain associated with pancreatic cancer. The company's innovative technology platform is designed to revolutionize how pain and other nerve-related conditions are treated. It features a catheter-based microchip sensing array antenna with the unique ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing solutions. Once problematic nerves are identified, Autonomix's proprietary radiofrequency (RF) ablation technology can precisely eliminate them, offering a highly targeted and minimally invasive therapeutic option for chronic pain, hypertension, and cardiology-related conditions. Hauser confirmed that 20 patients were enrolled in the initial PoC 1 trial, including the first five “lead-in” participants. Based on consistent and positive clinical outcomes that met the trial's primary objectives, the company determined that the patient sample was sufficient to conclude this initial phase. One of the most noteworthy findings was the demonstration of statistically significant pain relief in some patients as early as 24 hours post-procedure—highlighting the potential for rapid, meaningful clinical benefit. Importantly, the procedure also exhibited a strong safety profile. No device- or procedure-related serious adverse events were reported, underscoring the technique’s tolerability and risk mitigation potential in a highly vulnerable patient population. Encouraged by these early results, Autonomix is moving ahead with a follow-on PoC 2 phase of the study. This next phase will expand the treatment protocol to include additional visceral cancers as well as patients with earlier-stage pancreatic cancer experiencing moderate to severe pain. The ultimate goal remains to evaluate the effectiveness of RF ablation in managing cancer-related pain and improving patients’ quality of life. Although the catheter-based microchip sensing array—a core feature of the Autonomix platform—was not used in this initial trial, it is expected to be evaluated in future studies. The sensing array is anticipated to play a key role in future applications by enabling real-time, ultra-sensitive nerve mapping to enhance targeting accuracy and clinical outcomes. #proactiveinvestors #autonomixmedcialltd #nasdaq #amix #medical #nervoussystem #PancreaticCancer #CancerPainRelief #AutonomixMedical #BradHauser #OpioidAlternative #ClinicalTrials #MedicalTechnology #PainManagement #TransvascularTherapy #ProactiveInvestors